

## Special Issue

# Rheumatic Diseases: Pathophysiology, Targeted Therapy, Focus on Vascular and Pulmonary Manifestations 2022

### Message from the Guest Editors

Rheumatic diseases represent a heterogeneous group of severe autoimmune disorders. Patients with rheumatic diseases may present with a number of different vascular and pulmonary manifestations. The present Special Issue intends to provide an overview of the diversity and complexity of vascular and pulmonary manifestations of rheumatologic diseases in addition to gaps in knowledge to effectively manage them. Despite their significant morbidity and mortality we have only a limited understanding of their pathogenesis. We wish to provide an overview of the pathophysiology and current management approach of these disorders, highlighting tools which assist with diagnosis, risk stratification, and therapy. Finally, the importance of a multidisciplinary team using the skills of clinicians, radiologists, and pathologists will be highlighted.

---

### Guest Editors

Dr. Barbara Ruaro

Prof. Dr. Murray Baron

Dr. Edoardo Rosato

Prof. Dr. Romeo Martini

Prof. Dr. Marco Confalonieri

---

### Deadline for manuscript submissions

closed (26 January 2023)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/112149](https://mdpi.com/si/112149)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)